| Year Ending: | Total Revenue | Operating Income | Net Income |
| Dec-2022 | 96 | -308 (Loss) | -281 (Loss) |
| Dec-2021 | 55 | -216 (Loss) | -212 (Loss) |
| Dec-2020 | 31.4 | (128.1) (Loss) | (173.4) (Loss) |
| Dec-2019 | 10.7 | (100.7) (Loss) | (98.1) (Loss) |
| Dec-2018 | 4.7 | (67.1) (Loss) | (66.6) (Loss) |
| Dec-2017 | 4.1 | (42.1) (Loss) | (43.0) (Loss) |
Fate Therapeutics, Inc.
FATEFate Therapeutics, Inc. in brief
Fate Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. It was founded in 2007. Its market value was $264 M on 29 October 2026, which makes it the 15,278th largest listed company in the world and the 2,976th largest in the USA on this site. In the year to December 2025 it had sales of $7 M and a net loss of $136 M. It employs about 449 people and Bahram Valamehr is its chief executive. Its shares trade under the symbol FATE (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Fate Therapeutics, Inc.
Fate Therapeutics is a Clinical Stage Biopharmaceutical company. The company is dedicated to the development of next generation cellular immunotherapies for cancer and immune disorders. The headquarters is in USA.
Fate Therapeutics, Inc. timeline
- 2007
- 🏁· approximateFounded
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2013
- 🔔· approximateInitial public offering on Nasdaq
- 2022
- 💰Record revenue of $96 millionFY2022, the highest of the 8 years on record.
Events of Fate Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Fate Therapeutics, Inc.
- Layoffs
- It is planning to cut off 50% of employees i.e 315 employees and announcement made in Jan-2023.
Market cap history
World rank over time
Rank in USA: #1,782 (Jan 2020) · #697 (Jan 2021) · #1,166 (Jan 2022) · #1,967 (Dec 2022) · #2,858 (Jul 2023) · #2,758 (Jan 2024) · #1,807 (Mar 2026) · #2,869 (Aug 2026) · #2,978 (Oct 2026) · #2,980 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 39.7×
- Price / book
- 1.3×
- Free cash flow yield
- -42.5%
- Net margin
- -2049.9%
- Operating margin
- -2221.1%
- Return on equity
- -65.8%
- Liabilities / assets
- 35.0%
- Net debt
- $-172M
- Revenue growth
- -51.2%
- R&D / revenue
- 1621.5%
- Revenue per employee
- $15 K
- Profit per employee
- $-304 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $7M | -51.2% | $-148M | $-136M | -2049.9% |
| Dec 2024 | $14M | -78.5% | $-210M | $-186M | -1366.5% |
| Dec 2023 | $64M | -34.0% | $-191M | $-161M | -253.3% |
| Dec 2022 | $96M | +72.4% | $-308M | $-282M | -292.5% |
| Dec 2021 | $56M | +77.7% | $-217M | $-212M | -379.9% |
| Dec 2020 | $31M | +194.3% | $-128M | $-173M | -551.7% |
| Dec 2019 | $11M | +125.3% | $-101M | $-98M | -919.0% |
| Dec 2018 | $5M | — | $-67M | $-67M | -1405.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-106M | $6M | $-112M | $-1.15 | — |
| Dec 2024 | $-123M | $1M | $-124M | $-1.64 | — |
| Dec 2023 | $-132M | $6M | $-138M | $-1.64 | — |
| Dec 2022 | $-248M | $36M | $-284M | $-2.91 | — |
| Dec 2021 | $-163M | $51M | $-214M | $-2.24 | — |
| Dec 2020 | $-39M | $5M | $-44M | $-2.10 | — |
| Dec 2019 | $-83M | $7M | $-91M | $-1.44 | — |
| Dec 2018 | $-39M | $2M | $-41M | $-1.19 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-31M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 5, 20268-KCurrent reportMaterial agreement · Agreement ended
- Nov 5, 202610-QQuarterly report · period to Sep 2026
- Nov 5, 20268-KCurrent reportResults of operations
- Sep 28, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 15, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jun 4, 20268-KCurrent reportOther events
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 24, 2026DEF 14AProxy statement
- Feb 26, 202610-KAnnual report · period to Dec 2025
Official filings of Fate Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $7 M
- Operating income
- $-148 M
- Net income
- $-136 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $319 M
- Total liabilities
- $112 M
- Total equity
- $207 M
As of December-2025
FATE THERAPEUTICS - Annual Results Summary - in Million USD
Balance sheet
Total Assets as on Dec-2022 was 705 Million USD.
Total Liabilities as on Dec-2022 was 221 Million USD.
Total Equity as on Dec-2022 was 483 Million USD
Top 100 institutional investors in Fate Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Redmile Group, LLC | 12,872,946 | 0 (0.00%) | 10.59% | $31 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 7,105,172 | -193,723 (-2.65%) | 5.84% | $17 M | Nov 13, 2026 |
| 3 | Vanguard Portfolio Management LLC | 4,959,037 | +413,144 (+9.09%) | 4.08% | $12 M | Nov 13, 2026 |
| 4 | Acadian Asset Management LLC | 4,765,677 | +414,427 (+9.52%) | 3.92% | $11 M | Nov 9, 2026 |
| 5 | Vanguard Capital Management LLC | 4,496,086 | +50,550 (+1.14%) | 3.70% | $11 M | Nov 13, 2026 |
| 6 | Two Sigma Investments, LP | 3,905,357 | +315,494 (+8.79%) | 3.21% | $9 M | Nov 16, 2026 |
| 7 | Johnson & Johnson | 3,379,064 | 0 (0.00%) | 2.78% | $8 M | Oct 26, 2026 |
| 8 | Renaissance Technologies LLC | 2,374,394 | -608,874 (-20.41%) | 1.95% | $6 M | Nov 12, 2026 |
| 9 | Arrowstreet Capital, Limited Partnership | 2,374,346 | +2,344,170 (+7768.33%) | 1.95% | $6 M | Nov 13, 2026 |
| 10 | Millennium Management LLC | 2,167,548 | -266,430 (-10.95%) | 1.78% | $5 M | Nov 16, 2026 |
| 11 | Goldman Sachs Group Inc | 2,061,740 | +12,553 (+0.61%) | 1.70% | $5 M | Nov 16, 2026 |
| 12 | Qube Research & Technologies Ltd | 1,664,316 | +1,086,166 (+187.87%) | 1.37% | $4 M | Nov 13, 2026 |
| 13 | Susquehanna International Group, LLP | 1,563,709 | +1,052,659 (+205.98%) | 1.29% | $4 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 1,320,456 | -1,557 (-0.12%) | 1.09% | $3 M | Nov 6, 2026 |
| 15 | Assenagon Asset Management S.A. | 1,311,765 | +1,020,089 (+349.73%) | 1.08% | $3 M | Oct 15, 2026 |
| 16 | Bruce & Co., Inc. | 989,188 | 0 (0.00%) | 0.81% | $2 M | Nov 16, 2026 |
| 17 | Citadel Advisors LLC | 846,920 | -146,388 (-14.74%) | 0.70% | $2 M | Nov 16, 2026 |
| 18 | Connor, Clark & Lunn Investment Management Ltd. | 735,386 | +160,391 (+27.89%) | 0.60% | $2 M | Nov 10, 2026 |
| 19 | Morgan Stanley | 710,956 | +16,376 (+2.36%) | 0.58% | $2 M | Nov 13, 2026 |
| 20 | T. Rowe Price Investment Management, Inc. | 690,400 | -389,920 (-36.09%) | 0.57% | $2 M | Nov 16, 2026 |
| 21 | Charles Schwab Investment Management Inc | 654,963 | +44,014 (+7.20%) | 0.54% | $2 M | Nov 16, 2026 |
| 22 | Vanguard Fiduciary Trust Co | 640,428 | 0 (0.00%) | 0.53% | $2 M | Nov 13, 2026 |
| 23 | State Street Corp | 602,128 | +43,200 (+7.73%) | 0.50% | $1 M | Nov 12, 2026 |
| 24 | Dimensional Fund Advisors LP | 517,313 | +165,087 (+46.87%) | 0.43% | $1 M | Nov 4, 2026 |
| 25 | DAFNA Capital Management LLC | 500,000 | -25,000 (-4.76%) | 0.41% | $1 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Marshall Wace, LLP | 416,938 | -75,488 (-15.33%) | 0.34% | $1 M | Nov 13, 2026 |
| 27 | Privium Fund Management B.V. | 414,311 | 0 (0.00%) | 0.34% | $1 M | Nov 3, 2026 |
| 28 | Wellington Management Group LLP | 410,457 | +164,643 (+66.98%) | 0.34% | $1 M | Nov 16, 2026 |
| 29 | Man Group plc | 368,205 | +192,098 (+109.08%) | 0.30% | $1 M | Nov 16, 2026 |
| 30 | AQR Capital Management LLC | 352,086 | -3,485,143 (-90.82%) | 0.29% | $1 M | Nov 16, 2026 |
| 31 | Susquehanna Portfolio Strategies, LLC | 300,120 | -37,938 (-11.22%) | 0.25% | $1 M | Nov 16, 2026 |
| 32 | Invesco Ltd. | 294,342 | +28,360 (+10.66%) | 0.24% | $1 M | Nov 12, 2026 |
| 33 | Cerity Partners LLC | 288,554 | -53,178 (-15.56%) | 0.24% | $1 M | Nov 13, 2026 |
| 34 | Northern Trust Corp | 243,766 | +1,095 (+0.45%) | 0.20% | $1 M | Nov 16, 2026 |
| 35 | Schonfeld Strategic Advisors LLC | 231,659 | +165,501 (+250.16%) | 0.19% | $1 M | Nov 16, 2026 |
| 36 | Point72 Asset Management, L.P. | 209,501 | -232,727 (-52.63%) | 0.17% | $0 M | Nov 16, 2026 |
| 37 | Bridgeway Capital Management, LLC | 181,900 | -3,100 (-1.68%) | 0.15% | $0 M | Nov 16, 2026 |
| 38 | Empowered Funds, LLC | 181,900 | New | 0.15% | $0 M | Nov 13, 2026 |
| 39 | LPL Financial LLC | 172,746 | -31,000 (-15.22%) | 0.14% | $0 M | Nov 6, 2026 |
| 40 | UBS Group AG | 171,454 | -418,724 (-70.95%) | 0.14% | $0 M | Nov 10, 2026 |
| 41 | Bank Of America Corp /de/ | 163,509 | +9,803 (+6.38%) | 0.13% | $0 M | Nov 16, 2026 |
| 42 | HSBC Holdings PLC | 162,802 | -77,922 (-32.37%) | 0.13% | $0 M | Nov 16, 2026 |
| 43 | Woodline Partners LP | 159,650 | 0 (0.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 44 | Barclays PLC | 155,215 | -32,774 (-17.43%) | 0.13% | $0 M | Nov 6, 2026 |
| 45 | American Century Companies Inc | 153,722 | +74,803 (+94.78%) | 0.13% | $0 M | Nov 12, 2026 |
| 46 | Squarepoint Ops LLC | 152,247 | -1,377 (-0.90%) | 0.13% | $0 M | Nov 9, 2026 |
| 47 | Arete Wealth Advisors, LLC | 150,000 | 0 (0.00%) | 0.12% | $0 M | Nov 9, 2026 |
| 48 | Jacobs Levy Equity Management, Inc | 132,049 | New | 0.11% | $0 M | Nov 16, 2026 |
| 49 | Catalyst Funds Management Pty Ltd | 127,364 | New | 0.10% | $0 M | Nov 12, 2026 |
| 50 | Russell Investments Group, Ltd. | 126,492 | +20,690 (+19.56%) | 0.10% | $0 M | Nov 6, 2026 |
| 51 | Panagora Asset Management Inc | 125,954 | New | 0.10% | $0 M | Nov 12, 2026 |
| 52 | National Philanthropic Trust | 125,000 | 0 (0.00%) | 0.10% | $0 M | Nov 13, 2026 |
| 53 | Jump Financial, LLC | 124,047 | New | 0.10% | $0 M | Nov 13, 2026 |
| 54 | Gsa Capital Partners LLP | 119,781 | +7,514 (+6.69%) | 0.10% | $0 M | Nov 16, 2026 |
| 55 | XTX Topco Ltd | 108,180 | -72,646 (-40.17%) | 0.09% | $0 M | Nov 16, 2026 |
| 56 | Schulhoff & Co Inc | 100,000 | 0 (0.00%) | 0.08% | $0 M | Nov 13, 2026 |
| 57 | Jefferies Financial Group Inc. | 95,600 | +36,478 (+61.70%) | 0.08% | $0 M | Nov 5, 2026 |
| 58 | BNP Paribas Financial Markets | 75,705 | -195,929 (-72.13%) | 0.06% | $0 M | Nov 12, 2026 |
| 59 | ExodusPoint Capital Management, LP | 71,859 | New | 0.06% | $0 M | Nov 16, 2026 |
| 60 | SEI Investments Co | 70,980 | 0 (0.00%) | 0.06% | $0 M | Nov 10, 2026 |
| 61 | Corient Private Wealth LP | 67,024 | +509 (+0.77%) | 0.06% | $0 M | Nov 16, 2026 |
| 62 | Graham Capital Management, L.P. | 65,360 | +51,211 (+361.94%) | 0.05% | $0 M | Nov 16, 2026 |
| 63 | Wells Fargo & Company/mn | 60,115 | -3,531 (-5.55%) | 0.05% | $0 M | Nov 16, 2026 |
| 64 | EntryPoint Capital, LLC | 56,543 | New | 0.05% | $0 M | Nov 13, 2026 |
| 65 | Vanguard Personalized Indexing Management, LLC | 52,306 | +1,890 (+3.75%) | 0.04% | $0 M | Nov 16, 2026 |
| 66 | Ieq Capital, LLC | 49,330 | -438,398 (-89.89%) | 0.04% | $0 M | Nov 10, 2026 |
| 67 | Hudson Bay Capital Management LP | 47,500 | +22,340 (+88.79%) | 0.04% | $0 M | Nov 13, 2026 |
| 68 | FMR LLC | 46,857 | -2,219 (-4.52%) | 0.04% | $0 M | Nov 10, 2026 |
| 69 | Y-Intercept (Hong Kong) Ltd | 45,573 | +800 (+1.79%) | 0.04% | $0 M | Oct 16, 2026 |
| 70 | Vanguard Global Advisers, LLC | 43,754 | -47,957 (-52.29%) | 0.04% | $0 M | Nov 13, 2026 |
| 71 | Aster Capital Management (DIFC) Ltd | 42,584 | -134,016 (-75.89%) | 0.04% | $0 M | Nov 12, 2026 |
| 72 | Spark Investment Management LLC | 42,000 | New | 0.03% | $0 M | Nov 13, 2026 |
| 73 | WINTON GROUP Ltd | 40,400 | New | 0.03% | $0 M | Nov 12, 2026 |
| 74 | Abel Hall, LLC | 35,850 | -22 (-0.06%) | 0.03% | $0 M | Oct 19, 2026 |
| 75 | Brevan Howard Capital Management LP | 33,489 | New | 0.03% | $0 M | Nov 16, 2026 |
| 76 | HighTower Advisors, LLC | 32,000 | -1,454 (-4.35%) | 0.03% | $0 M | Nov 10, 2026 |
| 77 | Quantinno Capital Management LP | 28,930 | New | 0.02% | $0 M | Nov 13, 2026 |
| 78 | Focus Partners Wealth | 28,587 | -30,960 (-51.99%) | 0.02% | $0 M | Nov 12, 2026 |
| 79 | FPC Investment Advisory, Inc. | 26,456 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 80 | Citigroup Inc | 25,199 | +5,569 (+28.37%) | 0.02% | $0 M | Nov 4, 2026 |
| 81 | Captrust Financial Advisors | 23,317 | -50,295 (-68.32%) | 0.02% | $0 M | Nov 12, 2026 |
| 82 | Twinbeech Capital LP | 22,980 | New | 0.02% | $0 M | Nov 16, 2026 |
| 83 | Creative Planning | 22,699 | -86,281 (-79.17%) | 0.02% | $0 M | Nov 2, 2026 |
| 84 | Theory Financial LLC | 22,222 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 85 | Bronte Capital Management Pty Ltd. | 21,740 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 86 | Axq Capital, LP | 20,479 | -20,377 (-49.88%) | 0.02% | $0 M | Nov 12, 2026 |
| 87 | Moneta Group Investment Advisors LLC | 20,245 | New | 0.02% | $0 M | Nov 13, 2026 |
| 88 | SummitTX Capital, L.P. | 18,803 | New | 0.02% | $0 M | Nov 16, 2026 |
| 89 | Parametrica Management Ltd | 18,472 | 0 (0.00%) | 0.02% | $0 M | Oct 27, 2026 |
| 90 | Tiaa-Cref Individual & Institutional Services, LLC | 17,592 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 91 | Ameritas Advisory Services, LLC | 16,000 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 92 | Aigen Investment Management, LP | 15,268 | New | 0.01% | $0 M | Nov 16, 2026 |
| 93 | Deutsche Bank AG\ | 15,158 | 0 (0.00%) | 0.01% | $0 M | Nov 6, 2026 |
| 94 | Jane Street Group, LLC | 14,526 | -1,012,481 (-98.59%) | 0.01% | $0 M | Nov 12, 2026 |
| 95 | Neuberger Berman Group LLC | 13,688 | -3,008 (-18.02%) | 0.01% | $0 M | Nov 13, 2026 |
| 96 | Wealth Enhancement Advisory Services, LLC | 13,447 | -77,034 (-85.14%) | 0.01% | $0 M | Oct 13, 2026 |
| 97 | R Squared Ltd | 13,259 | +137 (+1.04%) | 0.01% | $0 M | Nov 6, 2026 |
| 98 | Susquehanna Fundamental Investments, LLC | 13,063 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 99 | Victory Capital Management Inc | 13,039 | +261 (+2.04%) | 0.01% | $0 M | Nov 10, 2026 |
| 100 | Narwhal Capital Management | 12,700 | 0 (0.00%) | 0.01% | $0 M | Nov 4, 2026 |
Mutual funds holding Fate Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 3.19 M | $9 M | 2.6% | <0.01% | +7.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc. | 2.96 M | $8 M | 2.4% | 0.07% | +17% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.15 M | $3 M | 0.95% | <0.01% | +4.1% | Jun 30, 2026 |
| 🇺🇸 Bruce FundBruce and Company Inc | 989,188 | $3 M | 0.81% | 0.71% | +25% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 876,106 | $2 M | 0.72% | 0.05% | −1.2% | May 29, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 786,810 | $2 M | 0.65% | 0.07% | +116% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc. | 629,759 | $2 M | 0.52% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 559,342 | $2 M | 0.46% | <0.01% | +4.2% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 535,817 | $2 M | 0.44% | <0.01% | +19% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 507,444 | $1 M | 0.42% | <0.01% | −1.6% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 378,180 | $1 M | 0.31% | 0.07% | +41% | Jun 30, 2026 |
| 🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc. | 308,409 | $1 M | 0.25% | 0.14% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 292,658 | $1 M | 0.24% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 256,360 | $1 M | 0.21% | 0.18% | +31% | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 233,942 | $1 M | 0.19% | 0.08% | +68% | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 228,044 | $1 M | 0.19% | 0.02% | −24% | Jul 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 192,817 | $1 M | 0.16% | <0.01% | +17% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 185,000 | $0 M | 0.15% | 0.34% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 151,779 | $0 M | 0.12% | <0.01% | +7.6% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 93,995 | $0 M | 0.08% | <0.01% | −17% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 83,030 | $0 M | 0.07% | 0.02% | +6.4% | May 31, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 85,542 | $0 M | 0.07% | <0.01% | +47% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 74,845 | $0 M | 0.06% | <0.01% | +144% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 70,190 | $0 M | 0.06% | <0.01% | +182% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 51,829 | $0 M | 0.04% | <0.01% | −19% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 50,020 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 53,650 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 45,952 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC | 44,894 | $0 M | 0.04% | 0.09% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 40,646 | $0 M | 0.03% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 38,835 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 37,837 | $0 M | 0.03% | <0.01% | −69% | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 37,797 | $0 M | 0.03% | <0.01% | +6.7% | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 25,983 | $0 M | 0.02% | 0.03% | +31% | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 23,800 | $0 M | 0.02% | <0.01% | −6.7% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 18,600 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 16,453 | $0 M | 0.01% | <0.01% | +7.9% | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 14,900 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 15,790 | $0 M | 0.01% | <0.01% | −80% | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 13,825 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 12,778 | $0 M | 0.01% | <0.01% | +1.5% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 8,193 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 7,593 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Thrivent Moderate Allocation PortfolioThrivent Financial for Lutherans | 7,568 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 7,309 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Thrivent Moderately Aggressive Allocation PortfolioThrivent Financial for Lutherans | 7,223 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 6,246 | $0 M | <0.01% | <0.01% | −29% | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 5,119 | $0 M | <0.01% | <0.01% | +8.6% | May 31, 2026 |
| 🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC | 5,379 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 4,268 | $0 M | <0.01% | <0.01% | −5.3% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 4,044 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 4,003 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 1 FundLincoln Financial Investments Corporation | 3,581 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 3,093 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation | 2,609 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 2,547 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Thrivent Aggressive Allocation PortfolioThrivent Financial for Lutherans | 2,300 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 2,059 | $0 M | <0.01% | <0.01% | −13% | Jun 30, 2026 |
| 🇺🇸 Thrivent Moderately Conservative Allocation PortfolioThrivent Financial for Lutherans | 1,825 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Core Equity FundJackson National Asset Management, LLC | 1,541 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Thrivent Global Stock PortfolioThrivent Financial for Lutherans | 1,440 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 575 | $0 M | <0.01% | <0.01% | +6.7% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 62 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Fate Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kamal AdawiChief Financial Officer | Sell | -6,582 | $2.055 | $14 K | 93,418 | Form 4 |
| filed | Bahram ValamehrPresident and CEO, Director | Sell | -43,947 | $2.460 | $108 K | 591,815 | Form 4 |
| filed | Cindy TahlSee Remarks | Sell | -38,800 | $2.460 | $95 K | 589,355 | Form 4 |
| filed | Cindy TahlSee Remarks | Sell | -25,590 | $1.880 | $48 K | 628,155 | Form 4 |
| filed | Bahram ValamehrPresident and CEO, Director | Sell | -28,946 | $1.880 | $54 K | 635,762 | Form 4 |
| filed | Cindy TahlSee Remarks | Option exercise | +122,220 | $1.320 | $161 K | 609,301 | Form 4 |
| filed | Cindy TahlSee Remarks | Option exercise | +44,444 | $1.050 | $47 K | 653,745 | Form 4 |
| filed | Robert S. EpsteinDirector | Option exercise | +25,000 | $1.690 | $42 K | 36,331 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Fate Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-6.49 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2014 | Q1 2014 | $0M |
Trading halts
- 2024-11-18 14:35 UTC, code LUDP, resumed 14:40 UTC
Fails to deliver
- : 475 shares at $2.17
- : 1,012 shares at $2.07
- : 220 shares at $1.79
- : 1,977 shares at $2.15
- : 4,007 shares at $2.37
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Fate Therapeutics, Inc. scorecard#
Passes 3 of the 18 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.3×Price to book 1.3× against Biotechnology's median of 2.9×.
- ✗Price to sales below its peers' median39.7×Price to sales 39.7× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-42.5%Free cash flow is -42.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-51.2%Revenue down 51.2% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-59.0%-59.0% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-59.0%-59.0% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.15 vs -1.64Diluted EPS -1.15 in fiscal 2025 against -1.64 the year before (report's currency).
- ✓Net income higher than five years earlier-$136 M-$136 M in fiscal 2025 against -$173 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$136 MNet income -$136 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-51.8%-51.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities5.8×Current ratio 5.79 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-6.18Z-score -6.18 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year4.5%Diluted shares up 4.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Fate Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Return on equity | -51.8% | -61.0% | |
| Revenue growth, 3 years a year | -59.0% | 12.9% | |
| Revenue growth | -51.2% | 15.8% |
1of 7on the Piotroski tests of financial strength
- Revenue fell 51.2% against the year before.
- Net loss of $136 million, the 15th loss-making year in a row.
- Free cash flow was negative: -$112 million.
Fate Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 6.6−51.2%100% | 14−78.5%100% | 64−34.0%100% | 96+72.4%100% | 56+77.7%100% | 31+194%100% | 11+125%100% | 4.7+15.4%100% | 4.1−6.7%100% | 4.4—100% | |
| Research and development | 108−20.1%1622% | 135−21.8%990% | 173−46.1%272% | 320+48.7%333% | 216+71.6%386% | 126+43.1%400% | 88+56.7%822% | 56+63.1%1182% | 34+29.9%837% | 26—601% | |
| General and administrative | 47−37.3%700% | 74−8.9%544% | 81−3.3%128% | 84+46.9%87.5% | 57+69.1%103% | 34+43.4%108% | 24+49.5%221% | 16+33.1%334% | 12+19.8%289% | 9.9—225% | |
| Operating expenses | 154−31.1%2322% | 224−11.9%1643% | 254−37.2%400% | 405+48.3%420% | 273+71.0%489% | 160+43.2%507% | 111+55.1%1043% | 72+55.4%1515% | 46+27.1%1126% | 36—826% | |
| Operating income | −148—−2222% | −210—−1543% | −191—−300% | −308—−320% | −217—−389% | −128—−407% | −101—−943% | −67—−1415% | −42—−1026% | −32—−726% | |
| Interest and finance income | 11−36.1%166% | 17+0.6%127% | 17+194%27.1% | 5.8+346%6.1% | 1.3−45.5%2.3% | 2.4−44.6%7.6% | 4.3+97.7%40.5% | 2.2+292%46.2% | 0.6+305%13.6% | 0.1—3.1% | |
| Interest expense and finance costs | — | — | — | — | 0—0.0% | 0−100%0.0% | 1.8+3.3%16.4% | 1.7+33.8%35.8% | 1.3−22.5%30.9% | 1.6—37.2% | |
| Other non-operating income (expense) | 11−52.6%171% | 24−18.8%176% | 30+10.9%46.6% | 27+451%27.7% | 4.8—8.7% | −45−1857%−144% | 2.6+422%24.1% | 0.5—10.4% | −0.8—−20.1% | −1.5—−34.1% | |
| Income tax | 0.0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | |
| Net income including minority interests | −136—−2051% | −186—−1366% | −161—−253% | −282—−293% | −212—−380% | −173—−552% | −98—−919% | −67—−1405% | −43—−1046% | −33—−760% | |
| Net income attributable to shareholders | −136—−2051% | −186—−1366% | −161—−253% | −282—−293% | −212—−380% | −173—−552% | −98—−919% | −67—−1405% | −43—−1046% | −33—−760% | |
| Earnings per share, basic | -1.15—— | -1.64—— | -1.64—— | -2.91—— | -2.24—— | -2.10—— | -1.44—— | -1.19—— | -1.02—— | -1.05—— | |
| Earnings per share, diluted | -1.15—— | -1.64—— | -1.64—— | -2.91—— | -2.24—— | -2.10—— | -1.44—— | -1.19—— | -1.02—— | -1.05—— | |
| Shares, weighted average (basic) | 119+4.5%— | 114+15.5%— | 98+1.6%— | 97+2.2%— | 95+15.0%— | 82—— | — | — | — | — | |
| Shares, weighted average (diluted) | 119+4.5%— | 114+15.5%— | 98+1.6%— | 97+2.2%— | 95+15.0%— | 82+20.8%— | 68+21.3%— | 56+33.9%— | 42+32.2%— | 32—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 47+29.3%14.6% | 36−13.9%8.2% | 42−31.7%8.3% | 61−54.1%8.7% | 134−20.2%14.5% | 167+67.7%26.9% | 100−47.6%33.0% | 191+114%89.4% | 89+0.4%84.5% | 89r89—93.2% | |
| Short-term investments | 157−35.4%49.2% | 243−11.1%55.1% | 273−27.1%54.0% | 375−22.3%53.1% | 482—52.3% | — | — | — | — | 3.5—3.7% | |
| Receivables | 0.9−74.1%0.3% | 3.5+93.8%0.8% | 1.8−95.3%0.4% | 38+344%5.5% | 8.7+57.3%0.9% | 5.5—0.9% | — | 0.5—0.2% | — | — | |
| Other current assets | 4.1−55.6%1.3% | 9.3−36.0%2.1% | 15−46.9%2.9% | 27+210%3.9% | 8.8+49.8%1.0% | 5.9+4.1%0.9% | 5.7+53.5%1.9% | 3.7+124%1.7% | 1.6+36.0%1.6% | 1.2—1.3% | |
| Current assets | 209−28.5%65.4% | 292−12.0%66.2% | 332−34.0%65.5% | 502−20.7%71.2% | 633+28.1%68.7% | 494+118%79.4% | 227+10.7%75.1% | 205+100%96.3% | 103+9.9%97.4% | 93—98.2% | |
| Property, plant and equipment | 57−11.6%17.8% | 64−33.5%14.6% | 97−12.0%19.1% | 110+20.2%15.6% | 92+183%9.9% | 32+183%5.2% | 11+123%3.8% | 5.1+101%2.4% | 2.6+61.5%2.4% | 1.6—1.7% | |
| Right-of-use (leased) assets | 42−10.5%13.0% | 47−24.6%10.6% | 62−6.7%12.2% | 66−6.6%9.4% | 71+5.4%7.7% | 67+195%10.8% | 23—7.5% | — | — | — | |
| Long-term investments | 1.5−94.7%0.5% | 28+2722%6.3% | 1.0−80.2%0.2% | 4.9−95.1%0.7% | 101—10.9% | — | 39—13.0% | — | — | — | |
| Total assets | 319−27.6%100% | 441−12.9%100% | 506−28.3%100% | 706−23.4%100% | 921+48.0%100% | 622+106%100% | 302+41.9%100% | 213+102%100% | 105+10.8%100% | 95—100% | |
| Accounts payable | 2.7−71.6%0.8% | 9.4+98.5%2.1% | 4.7−42.9%0.9% | 8.3−4.0%1.2% | 8.6+37.1%0.9% | 6.3+7.9%1.0% | 5.8+38.5%1.9% | 4.2+151%2.0% | 1.7+79.7%1.6% | 0.9—1.0% | |
| Debt due within a year | — | — | — | — | — | — | — | 2.4—1.1% | — | 8.2—8.6% | |
| Current liabilities | 36−6.4%11.3% | 39−1.5%8.7% | 39−65.7%7.7% | 114+40.3%16.2% | 81−5.0%8.8% | 86+208%13.7% | 28+2.0%9.2% | 27+147%12.8% | 11−27.2%10.5% | 15—16.0% | |
| Long-term debt | — | — | — | — | — | — | — | 12−16.0%5.8% | 15+492%14.1% | 2.5—2.6% | |
| Lease liabilities (non-current) | 73−5.9%23.0% | 78−20.0%17.7% | 97−6.1%19.2% | 104−5.1%14.7% | 109+16.3%11.9% | 94+272%15.1% | 25—8.3% | — | — | — | |
| Retained earnings | −1,534—−481% | −1,398—−317% | −1,212—−239% | −1,051—−149% | −769—−83.5% | −557—−89.5% | −384—−127% | −285—−134% | −219—−208% | −176—−185% | |
| Shareholders' equity | 207−35.0%65.0% | 319−13.5%72.3% | 368−23.9%72.8% | 484−28.7%68.6% | 679+76.6%73.7% | 384+57.1%61.8% | 245+52.5%81.0% | 160+108%75.3% | 77+5.5%73.3% | 73—77.0% | |
| Total liabilities and equity | 319−27.6%100% | 441−12.9%100% | 506−28.3%100% | 706−23.4%100% | 921+48.0%100% | 622+106%100% | 302+41.9%100% | 213+102%100% | 105+10.8%100% | 95—100% | |
| Shares outstanding | 115+1.3%— | 114+15.5%— | 99+1.4%— | 97+1.6%— | 96+9.1%— | 88+15.8%— | 76+17.1%— | 65+22.9%— | 53+27.2%— | 41—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 13−32.0%194% | 19+3.7%139% | 18+32.9%28.8% | 14+135%14.3% | 5.9+89.5%10.5% | 3.1+40.8%9.8% | 2.2+82.1%20.5% | 1.2+24.0%25.4% | 1.0+10.2%23.6% | 0.9—20.0% | |
| Share-based compensation | 25−39.9%375% | 41−4.5%304% | 43−44.8%68.4% | 79+44.8%81.8% | 54+76.8%97.3% | 31+76.6%97.8% | 17+177%163% | 6.3+74.5%133% | 3.6+13.3%87.8% | 3.2—72.3% | |
| Cash from operating activities | −106—−1596% | −123—−901% | −132—−208% | −248—−258% | −163—−292% | −39—−125% | −83—−779% | −39—−815% | −37r−37—−897% | −30—−677% | |
| Capital expenditure | −6.0—−89.6% | −0.7—−5.4% | −6.2—−9.7% | −36—−36.9% | −51—−90.8% | −4.9—−15.7% | −7.4—−69.2% | −2.3—−48.6% | −1.7—−42.0% | −0.5—−10.4% | |
| Cash from investing activities | 111+810%1673% | 12−89.2%89.6% | 113−32.4%177% | 167—173% | −324—−580% | −161—−512% | −157—−1474% | −0.5—−9.8% | −10—−248% | −4.1—−93.5% | |
| Debt issued | — | — | — | — | — | — | — | — | 15—365% | — | |
| Debt repaid | — | — | — | — | — | — | −15—−140% | — | −11—−262% | −7.7—−175% | |
| Shares issued | — | — | — | — | 412+118%737% | 189+16.2%601% | 162+20.7%1521% | 135+211%2839% | 43—1052% | — | |
| Cash from financing activities | 5.5−94.5%82.6% | 100+117420%733% | 0.1−99.1%0.1% | 9.2−98.0%9.6% | 453+60.2%811% | 283+88.6%900% | 150+6.5%1404% | 141+197%2970% | 47r47−18.0%1153% | 58—1312% | |
| Change in cash | 11—159% | −11—−79.0% | −20—−30.7% | −72—−75.0% | −34−141%−60.5% | 83—263% | −91−189%−849% | 102+29541%2145% | 0.3−98.6%8.4% | 24—541% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 4.8−33.4%100% | 0−100%— | 2.1+9.2%100% | 1.3−20.3%100% | 1.4*−26.4%100% | 1.7−43.4%100% | 1.9−71.8%100% | 1.6−15.4%100% | 1.9*+11.0%100% | 3.1—100% | 6.8—100% | 1.9—100% | 1.7*—100% | |
| Research and development | 99−14.9%2079% | 24−6.3%— | 24−11.1%1171% | 25−15.2%1902% | 25*−24.4%1857% | 26−25.4%1484% | 27−20.7%1438% | 29−9.3%1789% | 34*+5.6%1807% | 35—1127% | 35—511% | 32—1670% | 32*—1898% | |
| General and administrative | 37−27.4%782% | 8.0−24.5%— | 8.8−22.9%424% | 9.6−30.3%739% | 11*−30.1%779% | 11−48.9%611% | 11−33.7%600% | 14−34.0%845% | 15*−14.9%821% | 21—677% | 17—255% | 21—1083% | 18*—1070% | |
| Operating expenses | 136−25.3%2860% | 32−11.6%— | 33−14.6%1595% | 34−20.1%2640% | 36*−43.3%2636% | 36−34.2%2095% | 39−25.0%2039% | 43−19.0%2634% | 64*+27.9%3420% | 55—1804% | 52—766% | 53—2753% | 50*—2968% | |
| Operating income | −131—−2760% | −32—— | −31—−1495% | −33—−2540% | −35*—−2536% | −35—−1995% | −37—−1939% | −41—−2534% | −62*—−3320% | −52—−1704% | −45—−666% | −51—−2653% | −48*—−2868% | |
| Interest and finance income | 7.1−44.5%148% | 1.4−45.3%— | 1.6−46.8%74.7% | 1.9−44.0%144% | 2.2*−42.7%162% | 2.6−42.0%148% | 2.9−39.5%153% | 3.3−19.6%205% | 3.9*−12.2%208% | 4.4—144% | 4.8—71.3% | 4.1—216% | 4.4*—263% | |
| Other non-operating income (expense) | 6.7−64.2%140% | 1.6−37.2%— | 1.0−66.4%46.8% | 1.8−51.2%138% | 2.3*−75.5%171% | 2.5−47.1%143% | 2.9−56.5%152% | 3.7+19.4%225% | 9.6*+143%516% | 4.7—153% | 6.7—98.3% | 3.1—159% | 4.0*—236% | |
| Net income including minority interests | −124—−2620% | −31*—— | −30*—−1449% | −31—−2403% | −32*—−2365% | −32*—−1852% | −34*—−1787% | −38—−2309% | −52*—−2804% | −48*—−1551% | −38*—−567% | −48—−2494% | −44*—−2633% | |
| Net income attributable to shareholders | −124—−2620% | −31—— | −30—−1449% | −31—−2403% | −32*—−2365% | −32—−1852% | −34—−1787% | −38—−2309% | −52*—−2804% | −48—−1551% | −38—−567% | −48—−2494% | −44*—−2633% | |
| Earnings per share, basic | — | -0.25—— | -0.25—— | -0.26—— | — | -0.27—— | -0.29—— | -0.32—— | — | -0.40—— | -0.33—— | -0.47—— | — | |
| Earnings per share, diluted | — | -0.25—— | -0.25—— | -0.26—— | — | -0.27—— | -0.29—— | -0.32—— | — | -0.40—— | -0.33—— | -0.47—— | — | |
| Shares, weighted average (basic) | 124+3.9%— | 124+3.9%— | 120+1.6%— | 120+1.4%— | — | 119+1.0%— | 119+0.9%— | 118+17.1%— | — | 118—— | 117—— | 101—— | — | |
| Shares, weighted average (diluted) | 124+3.9%— | 124+3.9%— | 120+1.6%— | 120+1.4%— | — | 119+1.0%— | 119+0.9%— | 118+17.1%— | — | 118—— | 117—— | 101—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 44—18.4% | 44+8.2%18.4% | 32−21.4%12.5% | 40−11.9%13.9% | 47+29.3%14.6% | 41+7.2%11.8% | 41+11.7%11.1% | 45−63.0%11.3% | 36−13.9%8.2% | 38—7.7% | 37—7.0% | 121—21.3% | 42—8.3% | |
| Short-term investments | 95—39.9% | 95−45.5%39.9% | 121−33.2%46.7% | 135−30.8%47.5% | 157−35.4%49.2% | 175−32.5%50.9% | 182−32.2%48.9% | 196—49.0% | 243−11.1%55.1% | 259—52.3% | 268—50.7% | — | 273—54.0% | |
| Receivables | 0.5—0.2% | 0.5−29.8%0.2% | 0.7−49.6%0.3% | 0.7−70.7%0.2% | 0.9−74.1%0.3% | 0.7−83.5%0.2% | 1.4+33.1%0.4% | 2.4+180%0.6% | 3.5+93.8%0.8% | 4.1—0.8% | 1.0—0.2% | 0.9—0.2% | 1.8—0.4% | |
| Other current assets | 4.6—2.0% | 4.6−9.7%2.0% | 3.5−43.6%1.3% | 4.0−25.7%1.4% | 4.1−55.6%1.3% | 5.1−44.3%1.5% | 6.2−54.1%1.7% | 5.4−46.0%1.4% | 9.3−36.0%2.1% | 9.2—1.9% | 13—2.5% | 10.0—1.7% | 15—2.9% | |
| Current assets | 144—60.5% | 144−34.8%60.5% | 158−31.4%60.7% | 180−27.7%63.0% | 209−28.5%65.4% | 221−28.7%64.4% | 230−27.9%62.0% | 248−37.1%62.3% | 292−12.0%66.2% | 310—62.7% | 319—60.4% | 394—69.2% | 332—65.5% | |
| Property, plant and equipment | 49—20.5% | 49−17.8%20.5% | 52−15.6%19.8% | 54−13.5%19.0% | 57−11.6%17.8% | 59−27.8%17.3% | 61−30.2%16.4% | 63−31.9%15.7% | 64−33.5%14.6% | 82—16.6% | 88—16.6% | 92—16.2% | 97—19.1% | |
| Right-of-use (leased) assets | 40—16.8% | 40−5.7%16.8% | 41−7.4%15.6% | 41−9.1%14.4% | 42−10.5%13.0% | 42−27.4%12.3% | 44−26.4%11.8% | 45−25.5%11.3% | 47−24.6%10.6% | 58—11.8% | 60—11.3% | 61—10.6% | 62—12.2% | |
| Long-term investments | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 1.5−94.7%0.5% | 10−69.3%3.0% | 26−44.7%7.0% | 32+325%8.1% | 28+2722%6.3% | 34—6.8% | 47—8.9% | 7.6—1.3% | 1.0—0.2% | |
| Total assets | 238—100% | 238−30.7%100% | 260−30.0%100% | 285−28.5%100% | 319−27.6%100% | 344−30.6%100% | 372−29.7%100% | 399−30.0%100% | 441−12.9%100% | 495—100% | 529—100% | 570—100% | 506—100% | |
| Accounts payable | 2.9—1.2% | 2.9−16.5%1.2% | 3.3−19.4%1.3% | 3.3−21.8%1.2% | 2.7−71.6%0.8% | 3.5−44.8%1.0% | 4.0−26.5%1.1% | 4.2−38.1%1.1% | 9.4+98.5%2.1% | 6.3—1.3% | 5.5—1.0% | 6.8—1.2% | 4.7—0.9% | |
| Current liabilities | 33—13.7% | 33+16.3%13.7% | 33+13.7%12.5% | 31+9.0%10.8% | 36−6.4%11.3% | 28−24.9%8.2% | 29−17.6%7.7% | 28−37.9%7.1% | 39−1.5%8.7% | 37—7.6% | 35—6.6% | 45—8.0% | 39—7.7% | |
| Lease liabilities (non-current) | 69—29.1% | 69−6.9%29.1% | 71−6.5%27.2% | 72−6.2%25.3% | 73−5.9%23.0% | 74−19.1%21.7% | 76−19.4%20.4% | 77−19.7%19.3% | 78−20.0%17.7% | 92—18.6% | 94—17.8% | 96—16.8% | 97—19.2% | |
| Retained earnings | −1,626—−683% | −1,626—−683% | −1,596—−613% | −1,566—−549% | −1,534—−481% | −1,502—−437% | −1,470—−395% | −1,436—−360% | −1,398—−317% | −1,346—−272% | −1,298—−245% | −1,260—−221% | −1,212—−239% | |
| Shareholders' equity | 133—55.8% | 133−43.2%55.8% | 153−41.3%59.0% | 180−37.7%63.1% | 207−35.0%65.0% | 234−35.4%68.1% | 261−34.2%70.3% | 288−32.3%72.3% | 319−13.5%72.3% | 362—73.2% | 397—75.1% | 426—74.8% | 368—72.8% | |
| Total liabilities and equity | 238—100% | 238−30.7%100% | 260−30.0%100% | 285−28.5%100% | 319−27.6%100% | 344−30.6%100% | 372−29.7%100% | 399−30.0%100% | 441−12.9%100% | 495—100% | 529—100% | 570—100% | 506—100% | |
| Shares outstanding | 122—— | 122+5.4%— | 117+1.8%— | 116+1.5%— | 115+1.3%— | 115+1.3%— | 115+0.7%— | 115+0.7%— | 114+15.5%— | 114—— | 114—— | 114—— | 99—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 11−21.9%241% | 2.7*−17.0%— | 2.8*−15.2%134% | 2.9−12.5%225% | 3.1*−36.4%224% | 3.2*−30.0%185% | 3.3*−30.6%172% | 3.3−30.9%205% | 4.8*−1.5%259% | 4.6*—150% | 4.7*—69.7% | 4.8—250% | 4.9*—291% | |
| Share-based compensation | 16−45.0%330% | 2.7−44.5%— | 3.5−50.8%169% | 3.9−46.8%302% | 5.5*−39.4%404% | 4.9−58.7%279% | 7.2−25.7%375% | 7.4−32.8%453% | 9.1*−3.7%490% | 12—383% | 9.6—142% | 11—570% | 9.5*—565% | |
| Cash from operating activities | −105—−2218% | −28—— | −23—−1124% | −31—−2373% | −23*—−1703% | −24*—−1400% | −25*—−1289% | −34—−2075% | −28*—−1495% | −29*—−957% | −32*—−477% | −33—−1732% | −37*—−2186% | |
| Capital expenditure | −1.5—−31.8% | 0*—— | −0.1*—−3.8% | −0.2—−18.4% | −1.2*—−87.1% | −2.2*—−127% | −1.4*—−71.4% | −1.2—−73.4% | −0.1*—−5.3% | −0.5*—−16.1% | −0.1*—−0.8% | −0.1—−4.5% | −0.2*—−10.8% | |
| Cash from investing activities | 93−12.9%1950% | 27*+26.2%— | 15*−25.7%699% | 24−44.7%1816% | 28*+21.1%2018% | 21*−16.5%1222% | 20*—1027% | 43+146%2620% | 23*−49.7%1227% | 25*—828% | −53*—−788% | 17—899% | 45*—2706% | |
| Shares issued | — | 7.6—— | — | — | — | — | — | — | — | — | −0.1—−1.5% | 75—3877% | — | |
| Cash from financing activities | — | 7.6*+208%— | — | — | 1.7*−46.0%123% | 2.5*—142% | 1.3*+4.0%69.5% | 0−100%0.0% | 3.1*—168% | 0*—0.0% | 1.3*—18.8% | 95—4960% | −0.2*—−10.7% | |
| Change in cash | −1.8−167%−38.0% | 6.6*—— | −7.1*—−343% | −7.2−182%−557% | 6.0*—439% | −0.6*—−36.0% | −3.7*—−193% | 8.9−88.8%544% | −1.9*−122%−99.6% | −4.0*—−129% | −84*—−1246% | 79—4127% | 8.5*—509% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Fate Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Bahram Valamehr | $2.2 M | $1.6 M | $913 K | $10 |
| 2024J. Scott Wolchko | $4.2 M | $1.6 M | $3.5 M | $16 |
| 2023J. Scott Wolchko | $3.5 M | −$360 K | $2.9 M | $37 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Fate Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Directors and officers 9 · Material agreement 2 · Agreement ended 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| RestructuringResults announced | 8-K | |
| Shareholder vote | 8-K/A | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2020 | $50 M | Private placement after listing | $50 to $250 million | 1 | equity | SEC |
| Apr 2020 | $50 M | Private placement after listing | $50 to $250 million | 1 | equity | SEC |
| Nov 2016 | $57 M | Private placement after listing | $50 to $250 million | 21 | equity | SEC |
| Aug 2016 | $10 M | Private placement after listing | $10 to $50 million | 4 | equity | SEC |
| May 2015 | $8 M | Private placement after listing | $2 to $10 million | 1 | equity | SEC |
| May 2012 | $9 M | No. 2 | $2 to $10 million | 17 | equity | SEC |
| Nov 2009 | $36 M | No. 1 | $10 to $50 million | 18 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Fate Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $122 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Scientist, In Vivo PharmacologyMolecular and Cellular Biologists | 2 | $122 K |
Where: San Diego, CA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 2 | 2 | $122 K | 2 |
| FY2025 | 3 | 3 | $125 K | 3 |
| FY2024 | 2 | 2 | $130 K | 2 |
| FY2023 | 10 | 10 | $107 K | 11 |
| FY2022 | 6 | 6 | $108 K | 7 |
| FY2021 | 7 | 7 | $95 K | 7 |
| FY2020 | 6 | 6 | $83 K | 6 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Fate Therapeutics, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2023 | 315 | · | · | · | · | · | · | · | · | · | · | · | 315 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 12% of workforce | Restructuring planSEC 8-K | “In connection with the Restructuring, the Company committed to a reduction in total workforce by approximately 12% (the “RIF”).” | Filing | |
| effective | 217 people | LayoffWARN notice | San Diego, California | Notice list |
| effective | 43 people | LayoffWARN notice | San Diego, California | Notice list |
| effective | 34 people | LayoffWARN notice | San Diego, California | Notice list |
| effective | 21 people | LayoffWARN notice | South San Francisco, California | Notice list |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Fate Therapeutics, Inc. compares in Biotechnology
- Market cap$264 M · higher than 49% of 726
- Revenue$7 M · higher than 38% of 647
- Revenue growth-51.2% · higher than 17% of 438
- Price / sales39.7× · lower than 21% of 339
- Price / book1.3× · lower than 73% of 534
- FCF yield-42.5% · higher than 27% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Fate Therapeutics, Inc.🇺🇸 | $264 M | — | — | -51.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on 2021
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Fate Therapeutics, Inc.? Verify and update this profile — free
Show Fate Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.